Evidence mapPaperPMID 40225326Full record

Trial reportFrontiers in endocrinology2025

Factorial design study of self-management using Dnurse App in T2DM patients.

Hongxia Tang, Huiwen Tan, Jihong Zhang, Mingjiao Zhang, Mengjie Chen, Laixi Kong, Xiaoxia Wang, Maoting Guo, Jinxiu Zhao, Lili Song and 4 more

Abstract readEquivalence TrialMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hongxia Tang *School of Nursing, Chengdu Medical College, Chengdu, Sichuan, China.
Huiwen Tan *Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Jihong Zhang *The School Hospital, Southwest Petroleum University, Chengdu, Sichuan, China.
Mingjiao ZhangSchool of Nursing, Chengdu Medical College, Chengdu, Sichuan, China.
Mengjie ChenSchool of Nursing, Chengdu Medical College, Chengdu, Sichuan, China.
Laixi KongSchool of Nursing, Chengdu Medical College, Chengdu, Sichuan, China.
Xiaoxia WangSchool of Nursing, Chengdu Medical College, Chengdu, Sichuan, China.
Maoting GuoSchool of Nursing, Chengdu Medical College, Chengdu, Sichuan, China.
Jinxiu ZhaoDepartment of Neurology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China.
Lili SongSchool of Nursing, Chengdu Medical College, Chengdu, Sichuan, China.
Zijun ZhengSchool of Nursing, Chengdu Medical College, Chengdu, Sichuan, China.
Huiqi YangDepartment of Nursing, Nanbu People's Hospital, Nanchong, Sichuan, China.
Zhe LiMental Health Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Zhenzhen XiongSchool of Nursing, Chengdu Medical College, Chengdu, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: With the popularity of smart phones and the development of information technology, more and more patients are adopting diabetes APPs for self-management. However, at present, there are few research reports on the effect of those APPs coming from China. Objective: The purpose of this study was to evaluate the effectiveness and applicability of an APP for blood glucose control that is widely popular among Chinese patients with type 2 diabetes mellitus (T2DM). Methods: This is a 2-center, factorial design, with equal proportional distribution, and superiority trial conducted in outpatient endocrinology clinics at two tertiary hospitals in Chengdu, China. The trial enrolled smartphone-literature individuals aged at least 18 years old who have been diagnosed with T2DM based on glycosylated hemoglobin A Results: 273 patients with type 2 diabetes were included in the study, among which 226 (82.8%) were followed up at the 3rd month and 220 (80.6%) at the 6th month. There was no significant difference in HbA Conclusions: The diabetes APP has a tendency to improve the HbA Clinical Trial Registration: https://www.chictr.org.cn, identifier ChiCTR2100042297.

Indexed as

Diabetes Mellitus, Type 2Mobile ApplicationsSelf-ManagementAdultAgedBlood GlucoseBlood Glucose Self-MonitoringChinaFemaleGlycated HemoglobinHumansMaleMiddle AgedBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanblood glucose monitoringChinesediabetes appfactorial design trialself-managementtype 2 diabetes mellitus

Identifiers

PMID40225326
PMCPMC11985454

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.